Two recent studies, by Casirati et al. and Wellhausen et al., report genetically engineering normal hematopoietic stem and progenitor cells (HSPCs) to be resistant to chimeric antigen receptor (CAR)-T cells, by changing a single amino acid in the target protein that abrogates CAR binding, without compromising protein function. This allows for selective targeting of cancer cells without harming normal hematopoietic cells.

Original languageEnglish
Pages (from-to)983-984
Number of pages2
JournalTrends in Cancer
Issue number12
StatePublished - Dec 2023


  • CAR T cells
  • HSPCs
  • epitope editing


Dive into the research topics of 'Making normal hematopoiesis invisible to CAR T cells'. Together they form a unique fingerprint.

Cite this